T-THERAPEUTICS LIMITED
The company is a biotechnology business developing bispecific T cell engagers for oncology and autoimmune diseases using its proprietary OpTiMus discovery platform.
Get an alert when T-THERAPEUTICS LIMITED files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Cash
£31m
+259.2% highest in 3 filed years
Net assets
£41m
+212.2% highest in 3 filed years
Employees
72
+4.3% highest in 3 filed years
Profit before tax
-£18m
-23.1% lowest in 3 filed years
Watchouts
Facts from the Companies House register and the latest accounts — not a rating
-
1 PSC ceased in last 24 months
Significant control changed hands — see the Ownership section.
Net assets
3-year trend · vs Health Care median
Accounts
3-year trend · Δ = latest vs prior filed period · latest reflected 2025-12-31
| Metric | Trend | 2023-12-31 | 2024-12-31 | 2025-12-31 | Δ vs prior |
|---|---|---|---|---|---|
| Turnover | — | — | — | — | |
| Operating profit | -£7,402,966 | -£15,521,090 | — | — | |
| Profit before tax | -£7,072,280 | -£15,016,801 | -£18,486,536 | -23.1% | |
| Net profit | -£5,789,282 | -£12,808,529 | -£16,292,150 | -27.2% | |
| Cash | £5,651,831 | £8,725,881 | £31,346,313 | +259.2% | |
| Total assets less current liabilities | £9,304,794 | £13,159,036 | £41,358,576 | +214.3% | |
| Net assets | £9,304,794 | £13,159,036 | £41,085,300 | +212.2% | |
| Equity | £9,304,794 | £13,159,036 | £41,085,300 | +212.2% | |
| Average employees | 33 | 69 | 72 | +4.3% | |
| Wages | £2,608,562 | £4,591,521 | £5,358,663 | +16.7% | |
| Directors' remuneration | £188,388 | £483,572 | £937,092 | +93.8% | |
| Directors' pension contributions | — | — | £58,436 | — | |
| Highest paid director | — | £404,207 | — | — |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. The Δ column is the change from the prior filed period as a percentage of |prior|; lines a company doesn't report show —. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Return on capital employed | -79.6% | -118.0% | — | |
| Gearing (liabilities / total assets) | 11.9% | 0.0% | 0.7% | |
| Current ratio | 6.27x | 3.91x | 10.01x |
Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Audit & accounting basis
- Accounting basis
- FRS 102
- Reporting scope
- Consolidated group
- Auditor
- RSM UK Audit LLP
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“The directors have concluded that the use of the going concern basis of accounting in the preparation of the financial statements remains appropriate.”
Group structure
- T-THERAPEUTICS LIMITED · parent
- T-Therapeutics Taiwan Co Ltd 100%
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
7 active · 2 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| BJORK, Samuel | Director | 2022-11-15 | Aug 1988 | American |
| BRADLEY, Allan, Dr | Director | 2022-05-10 | Feb 1960 | British |
| HAROLD, Theodora | Director | 2025-05-09 | Apr 1974 | British |
| HORGAN, Viet-Anh Anne | Director | 2025-12-01 | May 1976 | French |
| RAJAH, Luke Elliott | Director | 2025-10-22 | Aug 1987 | British |
| SEGHEZZI, Graziano | Director | 2022-11-15 | Feb 1969 | Italian,French |
| SINHA, Nihal | Director | 2022-11-15 | Aug 1984 | British |
Show 2 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| HUNG, David | Director | 2024-01-01 | 2025-11-30 |
| TANSLEY, Robert Giles, Dr | Director | 2022-11-15 | 2025-12-01 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Dr Allan Bradley | Individual | Shares 25–50%, Voting 25–50% | 2022-05-10 | Ceased 2025-05-14 |
Filing timeline
Last 20 of 56 total filings
Material constitutional events — rename, articles re-file, resolution
- 2025-12-05 MA Memorandum articles
- 2025-10-31 RESOLUTIONS Resolution
- 2025-10-31 MA Memorandum articles
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2026-09-09 | AA | accounts | Accounts with accounts type group | |
| 2026-08-27 | SH01 | capital | Capital allotment shares | |
| 2026-07-05 | SH01 | capital | Capital allotment shares | |
| 2026-06-09 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2026-04-29 | SH01 | capital | Capital allotment shares | |
| 2026-04-16 | SH01 | capital | Capital allotment shares | |
| 2026-02-16 | SH01 | capital | Capital allotment shares | |
| 2025-12-09 | AP01 | officers | Appoint person director company with name date | |
| 2025-12-08 | TM01 | officers | Termination director company with name termination date | |
| 2025-12-08 | TM01 | officers | Termination director company with name termination date | |
| 2025-12-05 | MA | incorporation | Memorandum articles | |
| 2025-11-07 | SH08 | capital | Capital name of class of shares | |
| 2025-11-07 | SH08 | capital | Capital name of class of shares | |
| 2025-11-03 | SH01 | capital | Capital allotment shares | |
| 2025-10-31 | RESOLUTIONS | resolution | Resolution | |
| 2025-10-31 | MA | incorporation | Memorandum articles | |
| 2025-10-29 | AP01 | officers | Appoint person director company with name date | |
| 2025-10-08 | RP01SH01 | miscellaneous | Legacy | |
| 2025-10-07 | CH01 | officers | Change person director company with change date | |
| 2025-10-01 | SH01 | capital | Capital allotment shares |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 20
- Capital events
- 9
- Officers appointed
- 2
- Officers resigned
- 2
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.